Aseptic manufacture of ganirelix acetate injection is the primary commercial downstream route for this peptide API. The aqueous formulation is compounded at 0.5 mg/mL expressed as ganirelix base, with mannitol at 25 mg per 0.5 mL syringe, and pH adjusted to 5.0 using glacial acetic acid and sodium hydroxide. The compounding vessel is a 316L stainless-steel jacketed tank held at 15–20°C to limit deamidation and aggregation. The bulk solution is prefiltered through a 0.45 µm PVDF membrane and then sterile-filtered through a 0.22 µm sterilizing-grade polyethersulfone membrane. Filling into siliconized Type I borosilicate-glass prefilled syringes is conducted under ISO 14644-1:2015 Class 5 conditions with Grade A unidirectional airflow. The aseptic process follows ISO 13408-1 and EudraLex Volume 4 Annex 1. Terminal sterilization is not applied because the peptide degrades under saturated steam conditions. The terminal finished product is a single-dose prefilled syringe delivering 250 µg ganirelix acetate per 0.5 mL by subcutaneous injection. Release and stability evaluations follow ICH Q1A(R2) and ICH Q3D; quality tests include USP <71> sterility, USP <85> bacterial endotoxins, USP <790> visible particulates, and USP <1207> container closure integrity. The process boundary is the filtered bulk hold time, typically not more than 24 h at 2–8°C unless microbial challenge and stability data support extension.

What Limits Terminal Sterilisation of Ganirelix Acetate Injection?

Terminal sterilisation is limited by the thermal lability of the peptide chain in aqueous solution. When a 250 µg/0.5 mL formulation is exposed to a saturated steam cycle at 121°C for 15 min, the primary degradation routes are deamidation of asparagine residues, peptide backbone hydrolysis, and soluble aggregate formation. These degradation products exceed ICH Q3B identification thresholds in forced degradation studies. Thermal stress also shifts pH when buffering capacity is consumed by hydrolytic products, moving the solution outside the 4.8–5.2 tolerance used for chemical stability. Aseptic filtration through a 0.22 µm membrane is therefore the sterility assurance method. The filter is integrity-tested before and after filling by bubble point, diffusion, or water intrusion methods aligned to ASTM F838-20. The filling line operates with Grade A unidirectional airflow, with settle plates, contact plates, and active air sampling documented per ISO 14698-1. Peptide adsorption to the filter membrane and tubing is controlled by preflushing the membrane with formulation buffer and by using polyethersulfone rather than nylon or cellulose acetate to reduce non-specific binding. The sterile filtrate is filled aseptically; no terminal heat treatment is added. This route is consistent with FDA 21 CFR 211.113 for microbiological contamination control and with EU GMP Annex 1 for sterility assurance. Process validation includes media fills on the same filling line with a broth volume approximating the 0.5 mL syringe fill volume, typically performed three times per shift with a target of 0 contaminated units.

Hospital pharmacy compounding of ganirelix acetate syringes from bulk peptide powder is operationally distinct from licensed finished-product manufacture. The compounding workflow is governed by USP <797> for compounding sterile preparations in the United States and by equivalent national rules in the EU, with the compounder working in an ISO Class 5 primary engineering control inside an ISO Class 7 buffer area. A batch is prepared by dissolving accurately weighed ganirelix acetate in sterile Water for Injection to a nominal concentration of 0.5 mg/mL, then adding mannitol as an isotonicity modifier to a final tonicity of approximately 250–350 mOsm/kg. The solution is sterile-filtered through a 0.22 µm syringe-tip membrane filter into a sterile vial or syringe. Because compounders cannot replicate the validated aseptic line, the beyond-use date is short: for a low-risk compounded sterile preparation prepared under ISO Class 5, the default maximum storage is 9 days at 2–8°C or 24 h at room temperature unless a longer stability study is available. The terminal product is a patient-specific subcutaneous syringe for use in a fertility clinic, labelled with active substance, strength, volume, beyond-use date, storage temperature, and a caution that the preparation is not the licensed ready-to-use syringe. The main incompatibility is with silicone oil: prolonged contact between an agitated ganirelix acetate solution and siliconized syringe barrels can increase subvisible particle counts and accelerate aggregate growth. Low-silicone or silicone-free syringes are preferred for compounding. Sterility testing is performed per USP <71> and bacterial endotoxin testing per USP <85> on each batch before release. The process is suitable only for facilities with peptide analytical capability, because ganirelix acetate lacks a harmonised USP monograph and release testing depends on a pharmacopoeial or validated HPLC method.

When Ganirelix Acetate Enters a Wet Granulation Stream

Tablet, capsule, and granule presentations of ganirelix acetate are not commercial products, and published data for oral solid formulations of this specific peptide is limited. The physical barrier to oral delivery is the peptide’s susceptibility to gastric peptidases and its negligible permeability across the intestinal epithelium. If oral solid dose development is attempted, wet granulation with an aqueous binder is contraindicated because the API undergoes hydrolysis and deamidation in contact with water at granulation temperatures. A dry granulation pathway using roller compaction or slugging is the only granulation route that avoids deliberate water contact; a typical investigational blend would contain ganirelix acetate, microcrystalline cellulose, lactose monohydrate, and a low-viscosity grade of crospovidone, with magnesium stearate added at 0.5–1.0 wt% after granulation. Process controls require relative humidity below 40% and product temperature below 25°C because the amorphous peptide powder is hygroscopic and agglomerates at higher moisture. Capsule filling is more feasible than tableting because tablet compression shear can induce peptide aggregation and reduce assay; a low-compression capsule fill using size 3 or 4 hard gelatin or HPMC capsules minimises the mechanical stress. Enteric coating may protect the API from gastric acid but does not solve intestinal permeability; permeation enhancer screening with medium-chain fatty acids or acyl carnitines is required. No oral ganirelix acetate product is approved by FDA, and no tablet or capsule formulation is listed in the FDA Orange Book. Finished oral products therefore remain investigational, and any batch produced for animal pharmacokinetic or first-in-human studies is manufactured under current Good Manufacturing Practice for investigational medicinal products with a stability protocol under ICH Q1A(R2). The granule intermediate is compressed into tablets or filled into capsules only after drying to a loss-on-drying of 2.0% or less.

Prefilled Syringe Componentry, Silicone Oil Migration, and Leachables Control

The selected primary packaging for ganirelix acetate injection is a Type I borosilicate-glass syringe barrel with a bromobutyl plunger stopper and a stainless-steel needle. The barrel is siliconized to allow smooth plunger movement, but free silicone oil droplets can act as nucleation sites for peptide aggregation. Component qualification follows FDA 21 CFR 211.94 for drug product containers and closures and Ph Eur 3.2.1 or ISO 4802-1 for glass. Silicone oil migration is evaluated by extracting the syringe with a suitable solvent and quantifying polydimethylsiloxane by Fourier transform infrared spectroscopy or by liquid chromatography with an evaporative light scattering detector. A typical control limit for silicone oil in a 0.5 mL prefilled syringe is in the low sub-milligram range, and specific limits are justified by extractable studies. The stopper is assessed for volatile organic impurities and for extractables using USP <1663> and USP <1664>, while leachable testing is conducted on the filled finished product under accelerated conditions of 25°C/60% RH and 40°C/75% RH. The needle is 27-gauge thin-wall, 0.5 inch length, and the needle shield is elastomeric. A key incompatibility is tungsten oxide residue from the needle-forming process; tungsten pin residues can oxidise the peptide and increase related substances. Therefore, low-tungsten needles or siliconized barrels with reduced tungsten are specified in the quality agreement. Container closure integrity is verified by dye ingress using methylene blue or by vacuum decay per USP <1207>. Terminal process validation includes three consecutive media fill runs of at least 3,000 units each to detect a contamination rate below 0.1% with 95% confidence. The finished prefilled syringe is inspected for visible particles according to USP <790> and for subvisible particles according to USP <788>.

Subcutaneous Administration Protocols Create a Narrow Dose Precision Requirement

The clinical downstream use of ganirelix acetate prefilled syringes imposes a narrow dose-precision requirement on the filling line. The licensed dose is 250 µg once daily administered subcutaneously in the abdomen or upper thigh, usually starting on day 5 or 6 of ovarian stimulation and continuing until the injection of human chorionic gonadotropin. Because the fill volume is only 0.5 mL, the coefficient of variation for delivered volume must be controlled below 2.0% to keep the dose within the therapeutic range. Filling pumps are validated for dose accuracy using gravimetric checks of every fill head at start-up and after planned line stoppages. The injection is not diluted and not reconstituted, so the terminal product is the actual dose delivered to the patient. The ready-to-use syringe is stored at 25°C with permitted excursions from 15°C to 30°C, protected from light. Compliance with the approved label includes a contraindication for known hypersensitivity to ganirelix acetate or any excipient and a requirement that the single-dose syringe be discarded after use. The main processing risk at the clinical site is cold-chain excursion during distribution, so distribution simulation follows ASTM D4169 and thermal cycling studies are included in the stability program. The finished product is not suitable for intravenous administration and must not be mixed with other injections unless compatibility data exist. There is no tablet or capsule equivalent for this licensed route, because the peptide’s oral bioavailability is insufficient to maintain the same pharmacological effect.